Cytosurge AG and Bruker Corporation team up

A new partnership between Bruker Corporation and Cytosurge AG will allow researchers to integrate the force control, speed and resolution of Bruker’s PeakForce Tapping® technology with cell treatment precision and femtoliters scale fluid control of Cytosurge’s FluidFM.
Dr. Pascal Behr, CEO of Cytosurge AG, said: “Working together with Bruker as one of the world’s leading AFM providers marks an important milestone for Cytosurge. This new Premium partnership reinforces our vision of enabling the full potential of FluidFM technology for the benefit of researchers world-wide. We expect to see many exciting innovations and new applications when our technology is coupled with those of our partners. This new Premium collaboration with Bruker will enable us to deliver highly integrated and versatile FluidFM solutions based on Bruker’s state-of-the-art AFM product portfolio – starting today with the Bruker BioScope Resolve AFM.”

Executive Vice President and General Manager of Bruker’s AFM Business, David Rossi, said: “Partnering with Cytosurge to integrate FluidFM with BioScope Resolve and PeakForce Tapping technology fits perfectly with our strategy to take BioAFM experiments beyond imaging, from mechanobiology and drug delivery to the probing of biochemical interactions. Manipulating cells, and injecting biomolecules into cells while sensing piconewton forces, and imaging at the nanometer scale, are AFM capabilities that enable fundamentally new correlative information.”